Atrial fibrillation treatment with not-atiarrhythmical medicines (part II)
The modern understanding of way of profilactic and regression of atrium remodeling based on upstream therapy in patients with atrium fibrillation is presented based on literature and own clinical data. This type of arrhythmia develops as result of compound pathological process that is initiated by trigger and result in electrophysiologycal substrate forming and supporting this process. It is shown that inflammatory, oxidative stress, metabolism of atrium myocites, remodeling of extracellular matrix and fibrosis can be a potential therapeutics aims. The results of large trials that investigate the role of statins and ω-3 PSFA in profilactis of AF and their potential positive effects on atrium remodeling in AF patients.